The company provides a cell‑free mRNA platform that designs, synthesizes, and formulates therapeutic and vaccine candidates using in‑vitro transcription and proprietary lipid‑nanoparticle delivery. Its automated design suite and continuous‑flow bioprocessing compress development cycles from months to days and enable rapid scale‑up for global distribution. The platform serves pharmaceutical and biotechnology firms seeking accelerated mRNA‑based medicines.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development often depends on biologics that require animal-derived components, preservatives, and lengthy manufacturing cycles, which restricts rapid response to emerging health threats and limits accessibility for patients. Additionally, many diseases lack effective treatments due to slow pipeline progression and limited platform flexibility.
Solution
The company operates a messenger RNA (mRNA) platform that designs, synthesizes, and validates therapeutic and vaccine candidates by encoding the desired protein directly into synthetic mRNA. Using cell‑free in‑vitro transcription and lipid‑nanoparticle (LNP) delivery, the platform eliminates animal products and preservatives, enabling a more universally acceptable formulation. Its modular workflow supports parallel screening of multiple mRNA sequences, compressing design‑to‑clinical timelines from months to days. Scalable, continuous‑flow manufacturing processes allow rapid scale‑up for global distribution once a candidate demonstrates efficacy. Integrated preclinical and clinical data pipelines feed back into the design engine, continuously improving candidate selection and reducing development risk.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking accelerated vaccine or therapeutic development, as well as healthcare systems and patients that benefit from faster access to mRNA‑based medicines.
Features
- Cell‑free in‑vitro transcription system that produces high‑purity mRNA without animal‑derived reagents
- Proprietary lipid‑nanoparticle (LNP) formulation optimized for efficient cellular uptake and robust expression
- Automated design suite that generates and ranks multiple mRNA candidates in parallel within days
- Continuous‑flow bioprocessing platform enabling rapid scale‑up from gram to kilogram production volumes
- End‑to‑end analytics pipeline (sequencing, purity, potency) that validates each batch against regulatory standards
- Flexible platform architecture supporting vaccines, protein therapeutics, and gene‑editing applications across diverse indications
- Cloud‑based data integration linking preclinical, clinical, and manufacturing metrics to accelerate iterative optimization